FloraWorks

The page discusses CBN opportunities for B2B product innovation in the sleep supplement market.

FloraWorks shares updates on cannabinoid research, industry news, and insights.

New AHA data linking chronic melatonin use to a 90% higher risk of heart failure and nearly doubled mortality is accelerating a shift toward CBN, as TruCBN emerges as a non-hormonal, clinically backed sleep ingredient that supports deeper, safer, next-day-clear rest.

Multi-cannabinoid edibles with CBD, CBN, CBG, CBC, and THCv are overtaking THC-only products, hitting $2.5 billion by 2024, driven by consumer demand and scientific insights.

In a notable development within the biotech industry, FloraWorks, a leading company in cannabinoid research, is set to make a significant presentation at the upcoming Global Cannabinoid Research Society Conference.

SupplySide Supplement Journal published a feature on clinical cannabinoid research, including FloraWorks' work with TruCBN. The feature discusses rigorous research and scientific validation in the wellness industry.

In an unprecedented collaborative effort, FloraWorks and The Salk Institute have unveiled groundbreaking research elucidating the neuroprotective effects of cannabinoids on aging neuronal cells.

FloraWorks supplies non-intoxicating CBN and cannabinoids and supports wellness businesses.

FloraWorks provides support and pure materials for brands.

FloraWorks provides pure, tested CBN and cannabinoid ingredients for natural products.

FloraWorks USA's privacy policy describes how it collects, uses, and protects personal information and covers data rights and security measures.

FloraWorks' Terms & Conditions cover its B2B e-commerce platform, including governing law, user accounts, and product information. They took effect on April 3, 2023.